Reports
Measured and published by MAA. Public information only, with the method and its limits stated alongside. Free to quote, whether you are a member or not.
Published 2026-09-24 · Measured 2026-10-07
R&D Investment and Output, Korea's Listed Healthcare Sector — H1 2026
R&D, financials, headcount and export sales of 252 listed companies joined to approvals, trials, publications and patents · computed 2026-10-07 · published half-yearly
This report joins the R&D spend disclosed by Korea's listed healthcare companies to the approvals, trials, publications and patents the same companies produced over the same period. Tallies of R&D spend say how much was invested; what it turned into can only be counted once five sources are joined at the company level. Every figure is a tally of primary filings and regulatory or bibliographic records; methods and limitations are disclosed below. Free to quote and reuse with attribution to Medical AI Alliance (MAA), under CC BY 4.0.
Read in full →Published 2026-09-04 · Measured 2026-09-30
Listed Korea Healthcare R&D Scoreboard — Q3 2026
Full census of 403 KOSPI/KOSDAQ-listed medical AI, biotech and device companies · five public sources joined at the company level · computed 2026-09-30 · published quarterly
This scoreboard joins official records from Korea's MFDS, the US FDA, PubMed, KIPRIS and ClinicalTrials.gov at the company level to measure, each quarter, how research in Korea's listed healthcare sector converts into products and market entries. Every figure is a tally of primary regulatory records; methods and limitations are disclosed below. Citation is free with attribution to the MAA R&D Scoreboard.
Read in full →Published 2026-09-03 · Measured 2026-09-01
AI Visibility of Korea's Listed Healthcare Companies — Q3 2026
A full census of 400 listed companies · measured 2026-09-01 · published quarterly
Investors and overseas partners increasingly ask an AI assistant before they ask anyone else. That makes one question worth measuring: can AI actually read Korean healthcare and biotech companies?
Read in full →